Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022
Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million
Related news for (IMPL)
- Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of “Stalking Horse” Agreement to Facilitate Sale
- US Stocks Lower; Dow Falls Over 50 Points
- 12 Health Care Stocks Moving In Monday’s Pre-Market Session
- Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023
- Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023